--- title: Buy Tivicay (Dolutegravir) 50mg Tablets Online description: Tivicay (Dolutegravir) 50mg tablets treat HIV-1 in combination therapy for adults. Get from our secure verified pharmacy for confidential service. type: product language: en url: https://liabilis.com/order-tivicay-online-en.html availability: in_stock shipping: - type: Standard Airmail price: 10.00 currency: USD area: Worldwide time: 14-21 days - type: Tracked Express price: 30.00 currency: USD area: Worldwide tracking: true time: 5-9 days price_min: 137.56 price_max: 385.99 currency: USD offers: - name: 50mg x 30 tabs price: 137.56 - name: 50mg x 60 tabs price: 220.13 - name: 50mg x 90 tabs price: 296.99 - name: 50mg x 120 tabs price: 385.99 --- # Buy Tivicay (Dolutegravir) 50mg Tablets Online Tivicay, containing Dolutegravir, is an integrase strand transfer inhibitor developed by ViiV Healthcare for HIV-1 treatment. It prevents viral DNA integration into host cells, used in regimens for treatment-naive or experienced adults. This option supports viral load reduction. Available in 50mg tablets at our online pharmacy. ## Pricing and Options | Dosage | Pack Size | Price (USD) | Price Per Pill | Status | | :--- | :--- | :--- | :--- | :--- | | **50mg** | 30 tabs | **$137.56** | $4.59 | In Stock | | **50mg** | 60 tabs | **$220.13** | $3.67 | In Stock | | **50mg** | 90 tabs | **$296.99** | $3.30 | In Stock | | **50mg** | 120 tabs | **$385.99** | $3.22 | In Stock | [Buy Now](https://liabilis.com/order-tivicay-online-en.html) ## Introduction Tivicay contains the active compound dolutegravir, an integrase strand transfer inhibitor used primarily in combination therapy for HIV-1 infection in adults and children weighing at least 30 kg. Available as a tablet in 50 mg strength, it helps suppress viral replication and maintain immune function. Regulatory approvals from agencies like the FDA and EMA support its role in first-line and salvage regimens for treatment-naive or experienced patients. Specific information about secondary uses is limited, but it forms part of multi-drug regimens to reduce transmission risk and prevent progression to AIDS. ## Quick Reference Facts **Active Ingredient** : Dolutegravir **Form** : tablet 50 mg **Primary and Off-Label Uses** : Treatment of HIV-1 infection in combination with other antiretrovirals : Maintenance therapy in virologically suppressed adults : Pediatric use in children over 30 kg (approved) ## What is Tivicay? Tivicay is the generic version of medications containing the active compound dolutegravir. It is the generic equivalent of the brand-name Tivicay, originally developed by ViiV Healthcare and approved by the FDA in 2013. As a generic, Tivicay offers bioequivalence to the brand, meaning it delivers the same amount of active ingredient into the bloodstream at the same rate, ensuring comparable efficacy and safety. Generics like Tivicay provide significant cost savings-often 80-90% lower than brand versions-while meeting stringent regulatory standards for quality, purity, and stability. Marketed under brand names such as Tivicay, it is widely available internationally through licensed manufacturers. This accessibility makes it a practical option for long-term HIV management where affordability is key. ## How Tivicay Works Dolutegravir, the active ingredient in Tivicay, belongs to the class of integrase strand transfer inhibitors (INSTIs). HIV replicates by integrating its genetic material (viral DNA) into the host cell's DNA using the integrase enzyme. Tivicay binds to this enzyme, preventing the strand transfer step essential for viral integration, thereby halting the production of new virus particles. This mechanism provides rapid viral load reduction, often achieving undetectable levels within weeks when used in combination therapy. Onset of action occurs within hours of the first dose, with steady-state concentrations reached after 3-5 days. Dolutegravir is metabolized primarily by UGT1A1 enzymes in the liver and excreted mainly in feces, with a half-life of about 14 hours supporting once-daily dosing. Its high genetic barrier to resistance makes it effective against many HIV strains, including those resistant to older drug classes. Clinical studies, such as the SINGLE trial, demonstrate superior viral suppression compared to other regimens. ## Conditions Treated with Tivicay Tivicay is approved for the following indications based on regulatory data from the FDA, EMA, and WHO: - **HIV-1 infection in treatment-naive adults**: Dolutegravir's potent integrase inhibition rapidly lowers viral loads when combined with nucleoside reverse transcriptase inhibitors (NRTIs) like abacavir/lamivudine. Trials show 88-92% of patients achieving viral suppression at 48 weeks. - **HIV-1 infection in treatment-experienced adults**: Effective for integrase-naive patients or those with suppressed viremia switching regimens. It maintains control in virologically stable individuals, reducing resistance risk. - **HIV-1 infection in children and adolescents (≥30 kg)**: Approved for combination therapy, providing a child-friendly option with similar pharmacokinetics to adults, supporting growth and immune recovery. These uses stem from its ability to target a late stage of the HIV lifecycle, preserving CD4 cell counts and preventing disease progression. ## Is Tivicay the Right Medication for You? Tivicay suits adults and children (≥30 kg) with HIV-1 requiring combination antiretroviral therapy (ART), particularly treatment-naive patients or those stable on prior regimens seeking simplification. Guidelines from DHHS and EACS recommend it as a preferred INSTI due to efficacy, tolerability, and once-daily dosing without food restrictions. It is especially useful in resource-limited settings for its single-tablet potential in fixed-dose combinations. However, it may not be ideal for patients with known hypersensitivity to dolutegravir, severe hepatic impairment (Child-Pugh C), or concurrent use of dofetilide due to contraindications. Those with UGT1A1 poor metabolizer status or on strong inducers (e.g., rifampin) require dose adjustments. Consult your healthcare provider for personalized assessment based on viral load, resistance profile, and comorbidities. ## Buying Tivicay from [our online pharmacy](https://liabilis.com/order-tivicay-online-en.html) #### Why Choose Our Service? Accessing Tivicay can be challenging due to high brand costs or limited local availability, but [our online pharmacy](https://liabilis.com/order-tivicay-online-en.html) provides a reliable solution for affordable generic options. We help patients worldwide obtain quality medications at near-manufacturer prices, easing financial burdens for long-term therapy. #### Quality & Safety Assurance We facilitate access to medications through verified international partners operating under recognized regulatory frameworks. Every batch meets bioequivalence standards equivalent to the original brand, with rigorous testing for purity and potency. #### Pricing & Access Generic Tivicay offers substantial savings compared to brand equivalents like Tivicay, often at 70-90% lower cost through our platform. This makes effective HIV management more attainable, especially in regions with supply constraints or without insurance coverage. #### Discreet Delivery Privacy is paramount; we ship in plain, unmarked packaging to protect your confidentiality. Choose express delivery typically within 7 days or standard airmail in approximately 3 weeks, with tracking for peace of mind. Our service ensures secure, hassle-free access from our pharmacy. ## Use: Dosing, Missed Dose, Overdose Standard dosing for Tivicay (50 mg tablet) is one tablet once daily, taken orally with or without food, as part of combination ART. For patients on efavirenz, fosamprenavir/ritonavir, or tipranavir/ritonavir, the dose increases to 50 mg twice daily. Adjustments apply with carbamazepine, rifampin (50 mg twice daily), or in INSTI-experienced patients with certain resistance (consult guidelines). - **Missed dose**: Take as soon as remembered unless close to the next dose-do not double up. Consistent timing supports steady drug levels for viral control. - **Overdose**: Symptoms may include nausea, fatigue, or headache; seek immediate medical attention. Activated charcoal may be used if recent ingestion; dialysis is ineffective due to high protein binding. - **Precautions**: Avoid alcohol excess to minimize liver strain. No restrictions on driving, but report dizziness. Swallow whole; do not crush or split. ## Safety Information ### ⚠️ Who Should Not Take Tivicay Absolute contraindications include hypersensitivity to dolutegravir or excipients, and concurrent dofetilide use due to QT prolongation risk. Relative: severe liver disease or unexplained ALT elevation. ### Common Side Effects These occur in >5% of users and are usually mild: insomnia (up to 10%), headache (8%), nausea/diarrhea (5%). They often resolve within weeks; manage with hydration or over-the-counter remedies if approved by a provider. ### Serious Side Effects (Seek Immediate Medical Help) - Hypersensitivity reactions (rash, fever, organ dysfunction): Stop use and seek emergency care (1-2% incidence). - Hepatotoxicity (elevated liver enzymes): Monitor in hepatitis B/C co-infection. - Lactic acidosis or severe hepatomegaly (rare, <1%): Symptoms include muscle pain, breathing difficulty. - Neural tube defects risk in pregnancy (first trimester exposure). ### Drug & Food Interactions - **Dofetilide**: Contraindicated-risks cardiac arrhythmia. - **UGT1A1 inducers (rifampin, carbamazepine)**: Dose adjustment to 50 mg BID. - **Cations (antacids, multivitamins)**: Separate by 2 hours (affects absorption); no food interactions. - **Metformin**: Limit to 1,000 mg/day to avoid accumulation. ## Off-Label and Investigational Uses of Tivicay Clinical studies suggest dolutegravir is sometimes used off-label in multidrug-resistant HIV cases with integrase resistance mutations, guided by resistance testing. Investigational applications include hepatitis delta monotherapy (phase 2 data show viral suppression) and potential PrEP regimens, but these lack regulatory approval. Efficacy and safety for off-label uses have not been formally established by FDA or EMA; undertake only under direct supervision of a qualified healthcare provider. ## Storage & Handling Store Tivicay tablets at room temperature (20-25°C/68-77°F), away from moisture and light. Keep in original blister packaging until use. Discard after expiry date; do not use if discolored. For safe disposal, mix with unappetizing substance (e.g., coffee grounds) in sealed bag or return to pharmacy take-back programs. ## Frequently Asked Questions **Practical Use & Lifestyle** - **Can I take Tivicay with dairy or calcium-rich foods?** High-calcium foods or supplements can reduce absorption by chelating dolutegravir. Space intake by at least 2 hours or take with a light meal low in cations for optimal bioavailability. - **How does Tivicay fit into a daily exercise routine?** It causes no specific exercise restrictions, but monitor for fatigue if side effects occur. Hydration and timing doses consistently help maintain energy levels during workouts. - **Is Tivicay suitable for hot climates or travel?** Stable at up to 30°C if kept dry; use a pill organizer for time zone changes, maintaining once-daily intervals to avoid gaps in coverage. **Product & Formulation Details** - **What do Tivicay generic tablets look like?** Generics vary by manufacturer but are typically oval, film-coated tablets in green or yellow hues, imprinted with strength or code. Check packaging for identification. - **Can Tivicay tablets be split for easier swallowing?** No, as film-coating affects release; splitting risks uneven dosing. Whole tablets are designed for compliance. **Regulatory & Safety Nuances** - **What are considerations for elderly patients?** No dose adjustment needed, but monitor renal/hepatic function more closely due to age-related decline. Bioavailability remains consistent. - **Does Tivicay affect athletic drug testing?** It does not appear on standard doping panels or workplace screens, as it is not a controlled substance or performance enhancer. **Scientific & Clinical Curiosity** - **What key trials established Tivicay's efficacy?** The SINGLE and SPRING-2 trials compared dolutegravir to efavirenz and raltegravir, showing non-inferiority and better tolerability with 88% viral suppression at 48 weeks. - **How does dolutegravir compare to older INSTIs?** It has a higher resistance barrier than raltegravir or elvitegravir, with once-daily dosing and no boosting requirement, per WHO guidelines. ## Glossary **Integrase Strand Transfer Inhibitor (INSTI)** : A class of antiretrovirals that blocks HIV's integrase enzyme to prevent viral DNA integration into human cells. **Bioequivalence** : Proof that a generic delivers the same active ingredient amount and rate as the brand for identical clinical effect. **Viral Load** : Measure of HIV RNA copies in blood; suppression below 50 copies/mL indicates effective treatment. **UGT1A1** : Liver enzyme metabolizing dolutegravir; variations affect clearance in some patients. **CD4 Count** : Number of immune cells targeted by HIV; therapy aims to restore levels above 500 cells/μL. ## Disclaimer This article on Tivicay serves educational purposes only and cannot substitute for advice from a healthcare professional. Decisions about therapy, especially off-label applications, require oversight by a licensed provider. Readers are deemed capable adults responsible for their health choices. Our pharmacy service enables access to Tivicay, particularly generics, for those facing availability issues, high costs, or limited local options. Prior to initiating, modifying, or stopping any drug, discuss with your physician.